公开(公告)号：US12038445B2

公开(公告)日：2024-07-16

申请号：US16305718

申请日：2017-05-30

申请人： Human Metabolomics Institute, Inc.

发明人： Wei Jia

IPC分类号： G01N33/68 ,  G01N30/72 ,  G01N30/02

CPC分类号： G01N33/6893 ,  G01N30/7233 ,  G01N2030/025 ,  G01N2030/027 ,  G01N2800/085 ,  G01N2800/52

摘要： The present invention provides biomarker and biomarker panels useful for diagnostic methods evaluating liver disease status in a subject, monitoring liver disease, distinguishing between liver diseases, treating subjects evaluated by diagnostic methods of the invention, providing diagnostic tests for evaluating liver disease status in a subject, and kits there for.

公开(公告)号：US20220026398A1

公开(公告)日：2022-01-27

申请号：US17309062

申请日：2019-10-21

申请人： Human Metabolomics Institute Inc.

发明人： Wei JIA ,  Guoxiang XIE ,  Lu WANG

IPC分类号： G01N30/06 ,  B01L3/00 ,  G01N30/72

摘要： The present invention discloses a quantitative detection method of multiple metabolic components in a biological sample and a metabolic chip used in the method. The detection method includes performing derivatization treatment on the biological sample and then detecting the derivatized biological sample by liquid chromatography-mass spectrometry. During derivatization treatment, 3-nitrophenylhydrazine is used as a derivatization reagent, and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide is used as a derivatization reaction catalyst. According to the detection method of the present invention, high-sensitivity detection can be achieved, multiple metabolic components of different magnitudes can be detected, the operation is simple and fast, and the method is applicable to clinical detection and scientific research examination. The metabolic chip of the present invention includes a chip carrier microtiter plate and related reagents, and quantitative detection of multiple metabolic components of different magnitudes such as amino acid, phenol, phenyl or benzyl derivative, indole, organic acid, fatty acid, sugar, and bile acid in the biological sample on the same microtiter plate can be achieved.

公开(公告)号：US20200378991A1

公开(公告)日：2020-12-03

申请号：US16305718

申请日：2017-05-30

申请人： Human Metabolomics Institute, Inc.

发明人： Wei Jia

IPC分类号： G01N33/68 ,  G01N30/72

摘要： The present invention provides biomarker and biomarker panels useful for diagnostic methods evaluating liver disease status in a subject, monitoring liver disease, distinguishing between liver diseases, treating subjects evaluated by diagnostic methods of the invention, providing diagnostic tests for evaluating liver disease status in a subject, and kits there for.

公开(公告)号：US20240319210A1

公开(公告)日：2024-09-26

申请号：US18267469

申请日：2021-12-20

申请人： HUMAN METABOLOMICS INSTITUTE, INC.

发明人： Wei Jia ,  Guoxiang Xie ,  Kejun Zhou

IPC分类号： G01N33/72 ,  G01N30/02 ,  G01N30/72 ,  G01N30/88

CPC分类号： G01N33/728 ,  G01N30/7266 ,  G01N2030/027 ,  G01N2030/8822 ,  G01N2333/9108 ,  G01N2333/96419 ,  G01N2800/085

摘要： Disclosed in the present invention is an application of conjugated bilirubin as a biomarker in preparation of a diagnosis device for evaluating a risk of neonatal biliary atresia. Also disclosed in the present invention are a bilirubin content measurement method, a stable quantitative detection reagent for bilirubin, and an application of the quantitative detection reagent for bilirubin in preparation of a kit for measuring a content of the bilirubin and evaluating a risk of biliary atresia of a subject, infant hepatitis syndrome, α1 antitrypsin deficiency disease or Alagille syndrome. Also disclosed in the present invention are a kit for measuring the content of the bilirubin or evaluating the risk of neonatal biliary atresia, an application of the kit, a method for evaluating the risk of neonatal biliary atresia, and a device for predicting the risk of neonatal biliary atresia by using an expression level of the conjugated bilirubin. The present invention has the advantages of being simple and rapid, flexible in sample preparation, low in limit of detection, good in repeatability and high in sensitivity; and the sample preparation and detection method is simple and easy to implement, low in cost and suitable for popularization and use.

公开(公告)号：US20240255511A1

公开(公告)日：2024-08-01

申请号：US18564640

申请日：2022-05-27

申请人： HUMAN METABOLOMICS INSTITUTE, INC.

发明人： Wei Jia ,  Guoxiang Xie ,  Tianlu Chen

IPC分类号： G01N33/574 ,  G01N30/02 ,  G01N30/72 ,  G01N30/88

CPC分类号： G01N33/57438 ,  G01N30/7233 ,  G01N30/88 ,  G01N2030/027 ,  G01N2030/8822 ,  G01N2570/00

摘要： Provided in the present invention is a device for diagnosing liver cancer. The device determines the level of a biomarker in a biological sample of a subject to be a diagnostic indicator, wherein the level of the biomarker is selected from the level of one or more of taurocholic acid, taurochenodeoxycholic acid, glycocholic acid, glycochenodeoxycholic acid, linolelaidic acid (C18:2n6t), maltotriose, maltose and/or lactose, α-linolenic acid, β-alanine, sebacic acid, 2-methylvaleric acid, valeric acid, isovaleric acid and hexanoic acid, and/or the ratio of secondary bile acid to primary bile acid, and/or the ratio of glycine-conjugated primary bile acid to taurine-conjugated primary bile acid, the primary bile acid being selected from cholic acid and chenodeoxycholic acid, and the secondary bile acid comprising deoxycholic acid, lithocholic acid and ursodeoxycholic acid. The diagnosis device of the present invention can be used for early diagnosis of liver cancer and liver cirrhosis, thereby buying time for patients and improving the clinical treatment effect.